Literature DB >> 7744230

Insulin receptor tyrosine-kinase activity is altered in both muscle and adipose tissue from non-obese normoglycaemic insulin-resistant subjects.

G Grasso1, L Frittitta, M Anello, P Russo, G Sesti, V Trischitta.   

Abstract

We performed i.v. insulin tolerance test in 30 non-obese (BMI < 30 male and < 28 female) non-diabetic (by oral glucose tolerance test) subjects and subdivided them into three groups of 10 subjects each, according to their insulin sensitivity (K(itt) values). Then we compared the tyrosine-kinase activity of immunopurified insulin receptors (using 32P-ATP and poly-glu-tyr (4:1) from both muscle and adipose tissue in 7 of the most insulin-sensitive and 7 of the most insulin-resistant subjects. No difference was observed between the two groups in the basal (no insulin) receptor tyrosine-kinase activity from both tissues. In contrast, tyrosine-kinase activity response to insulin was significantly higher (p < 0.05 by 2-way ANOVA test) in receptors from both tissues of insulin-sensitive subjects. In addition, a decreased tyrosine-kinase sensitivity to insulin was observed in muscle, but not adipose, tissue of insulin-resistant subjects (insulin ED50 being 0.87 +/- 0.05 nmol/l vs 2.03 +/- 0.07, p < 0.05 in insulin-sensitive and -resistant subjects). Insulin ED50 of muscle receptor tyrosine-kinase significantly (p = 0.001) correlated to both K(itt) values (r = -0.79) and plasma insulin values at 120 min during OGTT (r = + 0.80). Insulin receptor content, as assessed by radioimmunoassay, was similar in both muscle (7.9 +/- 1.3 and 9.2 +/- 1.9 ng/mg protein) and adipose tissue (8.2 +/- 1.3 and 7.5 +/- 1.4) of insulin-sensitive and -resistant subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744230     DOI: 10.1007/BF02369353

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Arner; T Pollare; H Lithell; J N Livingston
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

2.  Human insulin receptor radioimmunoassay: applicability to insulin-resistant states.

Authors:  V Pezzino; V Papa; V Trischitta; A Brunetti; P A Goodman; M K Treutelaar; J A Williams; B A Maddux; R Vigneri; I D Goldfine
Journal:  Am J Physiol       Date:  1989-09

3.  The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Authors:  Y Ebina; L Ellis; K Jarnagin; M Edery; L Graf; E Clauser; J H Ou; F Masiarz; Y W Kan; I D Goldfine
Journal:  Cell       Date:  1985-04       Impact factor: 41.582

4.  Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein.

Authors:  G Sesti; A N Tullio; R D'Alfonso; M L Napolitano; M A Marini; P Borboni; R Longhi; L Albonici; A Fusco; A M Aglianò
Journal:  Acta Diabetol       Date:  1994-06       Impact factor: 4.280

5.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes.

Authors:  J F Caro; M K Sinha; S M Raju; O Ittoop; W J Pories; E G Flickinger; D Meelheim; G L Dohm
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

6.  Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.

Authors:  A Ullrich; J R Bell; E Y Chen; R Herrera; L M Petruzzelli; T J Dull; A Gray; L Coussens; Y C Liao; M Tsubokawa
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

7.  Insulin-mimetic anti-insulin receptor monoclonal antibodies stimulate receptor kinase activity in intact cells.

Authors:  G Steele-Perkins; R A Roth
Journal:  J Biol Chem       Date:  1990-06-05       Impact factor: 5.157

8.  Insulin receptor isotype expression correlates with risk of non-insulin-dependent diabetes.

Authors:  L Mosthaf; J Eriksson; H U Häring; L Groop; E Widen; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Insulin receptor tyrosine kinase activity is reduced in monocytes from non-obese normoglycaemic insulin-resistant subjects.

Authors:  L Frittitta; G Grasso; M E Munguira; R Vigneri; V Trischitta
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

10.  Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  A Handberg; A Vaag; J Vinten; H Beck-Nielsen
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

View more
  5 in total

Review 1.  Insulin action in skeletal muscle from patients with NIDDM.

Authors:  J R Zierath; A Krook; H Wallberg-Henriksson
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

Review 2.  Membrane glycoprotein PC-1 and insulin resistance.

Authors:  I D Goldfine; B A Maddux; J F Youngren; L Frittitta; V Trischitta; G L Dohm
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

Review 3.  Effects of exercise training on abdominal obesity and related metabolic complications.

Authors:  B Buemann; A Tremblay
Journal:  Sports Med       Date:  1996-03       Impact factor: 11.136

4.  PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity.

Authors:  L Frittitta; J Youngren; R Vigneri; B A Maddux; V Trischitta; I D Goldfine
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

Review 5.  The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities.

Authors:  Ira D Goldfine; Betty A Maddux; Jack F Youngren; Gerald Reaven; Domenico Accili; Vincenzo Trischitta; Riccardo Vigneri; Lucia Frittitta
Journal:  Endocr Rev       Date:  2008-01-16       Impact factor: 19.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.